Executive Committee

• Dr Julian Chick (Chief Executive Officer)
• Dr Jonathan Coates (Chief Scientific Officer)
• Dr Susan Cox (Senior Vice President Drug Development)
• Dr John Deadman (Senior Vice President Chemistry)
• Dr David Rhodes (Senior Vice President Biology)
• Mr Alan Boyd (CFO & Company Secretary)
• Ms Shameela Dermott (Senior Vice President Clinical Operations)

---

Dr Julian Chick (Chief Executive Officer)

Dr Chick was appointed as Chief Executive Officer and  executive Director of Avexa on 7 September 2004. He graduated with a PhD in Muscle Physiology from La Trobe University in 1998 and joined Amrad Corporation Limited as a Senior Business Development Manager in April 2002.

Prior to joining Amrad Corporation Limited, Dr Chick had five years experience as an investment adviser and financial consultant with Prudential-Bache Securities, BNP Paribas and Salomon Smith Barney. Dr Chick also spent time working for Foursight Associates as the ?principal analyst? reviewing investment opportunities for private equity investors and venture capitalists

---

Dr Jonathan Coates (Chief Scientific Officer)

Dr Coates obtained his Ph D from Glasgow University and has more than 24 years experience in antiviral drug discovery in the pharmaceutical industry. He spent 15 years in the UK at Glaxo Group Research and later Glaxo-Wellcome, where he filled various senior research roles and was one of the inventors of the anti-viral drug 3TC (Epivir for HIV and Zeffix for HBV). Dr Coates has extensive experience in leading program teams towards successful milestones, including clinical trials and three marketed drugs. Dr Coates joined Amrad Corporation in 1996 to establish a team to develop treatments for infectious diseases. Dr Coates now holds the position of Avexa's Chief Scientific Officer.

---

Dr Susan Cox (Senior Vice President Drug Development)

Dr Cox graduated with a PhD in Virology from the Karolinska Institute in 1991, and became an associate professor in 1994. She has 15 years experience in antiviral drug discovery. Dr Cox worked on the anti-CMV drug Foscavir ® at Astra, and was previously Program Director at Medivir, where she led antiviral research programs from discovery up to and including Phase II studies. Dr Cox joined Amrad Corporation Limited in 1998 and helped establish Avexa, where she currently holds the position of Senior Vice President Drug Development and is responsible for later stage projects.  She has recently been appointed to the Board of the International Society for Antiviral Research (ISAR) and is a graduate of the Australian Institute of Company Directors.  

---

Dr John Deadman (Senior Vice President Chemistry)

Dr Deadman obtained his Ph D in 1989 from the Institute of Cancer Research, London. Dr Deadman has more than twelve years experience in medicinal chemistry, drug design, and formulation/manufacturing aspects, first at the Thrombosis Research Institute and then as Head of Chemistry at Trigen, where he directed a program from discovery through to Phase II clinical trials. He is the author of more than 30 research papers and five patents. Dr Deadman moved to Amrad as Head of Chemistry in 2003 and now holds the position of Senior Vice President Chemistry at Avexa.

---

Dr David Rhodes (Senior Vice President Biology)

Dr Rhodes graduated with a PhD in Biochemistry from La Trobe University in 1994 and has more than 10 years experience in HIV research.  Dr Rhodes took up a post doctoral fellowship at the Fox Chase Cancer Centre in the US from 1994 to 1995.  In 1995, he returned to Australia to the Macfarlane Burnett Centre for Medical Research where he was previously Senior Research Officer.  Dr Rhodes joined the Amrad Corporation Limited in 2000 and presently holds the position of Senior Vice President Biology at Avexa.

---

Mr Alan Boyd (CFO & Company Secretary)

Mr Boyd has had over 23 years experience in finance, commencing his career and qualifying as a Chartered Accountant in the UK before emigrating to Australia in 1988.  Mr Boyd is also a qualified member of the ICAA and fellow of the CICSA.  After thirteen years in the accounting profession Mr Boyd became CFO and Company Secretary of an unlisted public company, later joining high profile listed dotcom Sausage Software Ltd in the same capacity.  Mr Boyd joined Amrad Corporation Ltd in November 2002 and under a service agreement provided financial and administrative services to Avexa from 1 July 2004 and company secretarial services from 1 July 2006 under a service agreement.  Mr Boyd formally joined Avexa on 1 April 2007.

---

Ms Shameela Dermott (Senior Vice President Clinical Operations)

Shameela Dermott obtained her BSc (Hons) in Pharmacology in 1997 from the University of Leeds, West Yorkshire. Shameela has obtained many years experience in the Pharmaceutical industry within Clinical, Project Management, Data Management, Programming, IVRS, Clinical Logistics and Business Development in the UK with PAREXEL, Fisher Clinical Services and PPD before emigrating to Australia in 2006. She joined Avexa in August 2006 as Clinical Research Manager and now holds the position of Senior Vice President Clinical Operations.